Acadia Pharmaceuticals Inc. (ACAD) Stock AnalysisACADAcadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $19.78 and a low RSI of 19.24, the stock is oversold but faces significant risks due to recent trial failures and analyst downgrades. The forward P/E ratio of 25.19 suggests that the stock may be overvalued based on future earnings expectations, despite a gross margin of 90.81%.

10 analysts cover ACAD: 8 rate it Buy, 2 Hold and 0 Sell. The average price target is 31.17.